Walleye Capital LLC Invests $834,000 in Maze Therapeutics, Inc. $MAZE

Walleye Capital LLC bought a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 27,945 shares of the company’s stock, valued at approximately $834,000. Walleye Capital LLC owned about 0.06% of Maze Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Janus Henderson Group PLC lifted its position in Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after buying an additional 2,390,713 shares during the last quarter. Vanguard Group Inc. increased its position in Maze Therapeutics by 218.1% during the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after acquiring an additional 915,342 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Maze Therapeutics by 3,868.5% in the third quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after acquiring an additional 758,104 shares during the period. Caligan Partners LP bought a new stake in shares of Maze Therapeutics in the 4th quarter worth about $22,794,000. Finally, Squadron Capital Management LLC bought a new stake in shares of Maze Therapeutics in the 4th quarter worth about $20,301,000.

Maze Therapeutics Stock Performance

Shares of NASDAQ:MAZE opened at $27.68 on Friday. The firm’s 50 day simple moving average is $27.10 and its 200-day simple moving average is $34.46. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. Maze Therapeutics, Inc. has a one year low of $12.81 and a one year high of $53.65. The firm has a market cap of $1.53 billion, a PE ratio of -10.94 and a beta of 2.14.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. As a group, equities analysts predict that Maze Therapeutics, Inc. will post -2.73 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on MAZE. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Truist Financial decreased their price objective on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, April 14th. JPMorgan Chase & Co. boosted their target price on Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, March 31st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $66.00.

Insider Buying and Selling at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 14,609 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.90, for a total value of $436,809.10. Following the completion of the sale, the chief marketing officer directly owned 14,609 shares in the company, valued at approximately $436,809.10. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $28.02, for a total value of $210,150.00. Following the transaction, the insider directly owned 26,250 shares in the company, valued at $735,525. The trade was a 22.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 141,470 shares of company stock valued at $3,887,939 in the last ninety days. Corporate insiders own 5.30% of the company’s stock.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.